Skip to main content

09 - References

References

796 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 9 References

  1. Martínez-­González L, et al. Incidence of anorexia nervosa in women: a systematic review and meta-­analysis. Int J Environ Res Public Health 2020; 17:3824.
  2. Galmiche M, et  al. Prevalence of eating disorders over the ­2000–­2018 period: a systematic literature review. Am J Clin Nutr 2019; 109:­1402–­1413.
  3. Nitsch A, et al. Medical complications of bulimia nervosa. Cleve Clin J Med 2021; 88:­333–­343.
  4. Chiappini S, et al. Exploring the nexus of binge eating disorder (BED), new psychoactive substances (NPS), and misuse of pharmaceuticals: charting a path forward. Expert Opin Pharmacother 2023; 24:­1915–­1918.
  5. Frank GKW. Pharmacotherapeutic strategies for the treatment of anorexia ­nervosa –­ too much for one drug? Expert Opin Pharmacother 2020; 21:­1045–­1058.
  6. National Institute for Health and Care Excellence. Eating disorders: recognition and treatment. NICE Guideline [NG69]. 2017 (last updated March 2020); https://www.nice.org.uk/guidance/ng69.
  7. American Psychiatric Association. Treatment of patients with eating disorders, third edition. Am J Psychiatry 2006; 163:­4–­54.
  8. Frank B, et al. Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents. J Eat Disord 2023; 11:151.
  9. Costandache GI, et al. An overview of the treatment of eating disorders in adults and adolescents: pharmacology and psychotherapy. Postep Psychiatr Neurol 2023; 32:­40–­48.
  10. Bauschka M, et al. Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-­control study. J Eat Disord 2023; 11:215.
  11. Thorey S, et al. Efficacy and tolerance of second-­generation antipsychotics in anorexia nervosa: a systematic scoping review. PLoS One 2023; 18:e0278189.
  12. Bissada H, et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-­blind, placebo-­controlled trial. Am J Psychiatry 2008; 165:­1281–­1288.
  13. Tahıllıoğlu A, et al. Is aripiprazole a key to unlock anorexia nervosa? A case series. Clin Case Rep 2020; 8:­2827–­2834.
  14. Frank GK, et al. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord 2017; 50:­447–­450.
  15. Himmerich H, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry 2023; 1–64.
  16. Court A, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res 2010; 44:­1027–­1034.
  17. Powers PS, et al. Double-­blind placebo-­controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev 2012; 20:­331–­334.
  18. Naguy A, et al. An adolescent male with anorexia nervosa favorably responded to mirtazapine. Am J Ther 2018; 25:­e675–­e676.
  19. Safer DL, et al. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report. Int J Eat Disord 2011; 44:­178–­181.
  20. Hrdlicka M, et al. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-­control study. Eur Child Adolesc Psychiatry 2008; 17:­187–­189.
  21. Andries A, et al. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 2014; 47:­18–­23.
  22. Claudino AM, et al. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006; 1:CD004365.
  23. Barbarich NC, et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int J Eat Disord 2004; 35:­10–­15.
  24. Rossi G, et al. Pharmacological treatment of anorexia nervosa: a retrospective study in preadolescents and adolescents. Clin Pediatr (Phila) 2007; 46:­806–­811.
  25. Keeler JL, et al. Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients 2021; 13:4158.
  26. Keeler JL, et al. Case report: intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa. Front Psychiatry 2023; 14:1181447.
  27. Keeler JL, et al. Novel treatments for anorexia nervosa: insights from neuroplasticity research. Eur Eat Disord Rev 2024; 32:­1069–­1084.
  28. Quagebeur R, et al. The role of short-­chain fatty acids (SCFAs) in regulating stress responses, eating behavior, and nutritional state in anorexia nervosa: protocol for a randomized controlled trial. J Eat Disord 2023; 11:191.
  29. Nagata JM, et al. Assessment of vitamin D among male adolescents and young adults hospitalized with eating disorders. J Eat Disord 2022; 10:104.
  30. Royal College of Psychiatrists. Medical emergencies in eating disorders (MEED). Guidance on recognition and management. College Report [CR233]. 2022; https://www.rcpsych.ac.uk/improving-­care/campaigning-­for-­better-­mental-­health-­policy/college-­reports/2022-­collegereports/cr233.
  31. Marvanova M, et al. Role of antidepressants in the treatment of adults with anorexia nervosa. Ment Health Clin 2018; 8:­127–­137.
  32. Walsh BT, et al. Time course of relapse following acute treatment for anorexia nervosa. Am J Psychiatry 2021; 178:­848–­853.
  33. Himmerich H, et al. Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. Pharmacol Ther 2020; 217:107667.
  34. Bacaltchuk J, et al. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003; 4:CD003391.
  35. Ghaderi A, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-­analysis. Peer J 2018; 6:e5113.
  36. Sysko R, et al. Early response to antidepressant treatment in bulimia nervosa. Psychol Med 2010; 40:­999–­1005.

Drug treatment of other psychiatric conditions CHAPTER 9 37. McElroy SL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-­controlled trial. Int J Eat Disord 2011; 44:­81–­90. 38. Hilbert A, et al. Meta-­analysis on the long-­term effectiveness of psychological and medical treatments for binge-­eating disorder. Int J Eat Disord 2020; 53:­1353–­1376. 39. McElroy SL, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-­eating disorder: a randomized clinical trial. JAMA Psychiatry 2015; 72:­235–­246. 40. Citrome L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved ­indication –­ what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015; 69:­410–­421. 41. Grilo CM, et al. Efficacy and safety of dasotraline in adults with binge-­eating disorder: a randomized, placebo-­controlled, fixed-­dose clinical trial. CNS Spectr 2021; 26:­481–­490. 42. Leombruni P, et al. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-­blind randomized controlled trial. Adv Ther 2006; 23:­481–­494. 43. Leombruni P, et  al. A 12 to 24  weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol 2006; 21:­181–­188.

No comments to display

Back to top